224 related articles for article (PubMed ID: 34379047)
1. Visualization of yellow fever virus infection in mice using a bioluminescent reporter virus.
Dong HL; Wang HJ; Liu ZY; Ye Q; Qin XL; Li D; Deng YQ; Jiang T; Li XF; Qin CF
Emerg Microbes Infect; 2021 Dec; 10(1):1739-1750. PubMed ID: 34379047
[TBL] [Abstract][Full Text] [Related]
2. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
[TBL] [Abstract][Full Text] [Related]
3. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
[TBL] [Abstract][Full Text] [Related]
4. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
[TBL] [Abstract][Full Text] [Related]
5. A mouse model for studying viscerotropic disease caused by yellow fever virus infection.
Meier KC; Gardner CL; Khoretonenko MV; Klimstra WB; Ryman KD
PLoS Pathog; 2009 Oct; 5(10):e1000614. PubMed ID: 19816561
[TBL] [Abstract][Full Text] [Related]
6. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
[TBL] [Abstract][Full Text] [Related]
7. Generation and Application of a Luciferase Reporter Virus Based on Yellow Fever Virus 17D.
Li D; Ye JL; Liu ZY
Virol Sin; 2021 Dec; 36(6):1456-1464. PubMed ID: 34342842
[TBL] [Abstract][Full Text] [Related]
8. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
[TBL] [Abstract][Full Text] [Related]
10. Use of Optical In Vivo Imaging to Monitor and Optimize Delivery of Novel Plasmid-Launched Live-Attenuated Vaccines.
Sharma S; Dallmeier K
Methods Mol Biol; 2022; 2412():283-294. PubMed ID: 34918251
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
Li LH; Liesenborghs L; Wang L; Lox M; Yakass MB; Jansen S; Rosales Rosas AL; Zhang X; Thibaut HJ; Teuwen D; Neyts J; Delang L; Dallmeier K
Mol Ther Methods Clin Dev; 2022 Jun; 25():215-224. PubMed ID: 35313504
[TBL] [Abstract][Full Text] [Related]
12. The yellow fever 17D virus as a platform for new live attenuated vaccines.
Bonaldo MC; Sequeira PC; Galler R
Hum Vaccin Immunother; 2014; 10(5):1256-65. PubMed ID: 24553128
[TBL] [Abstract][Full Text] [Related]
13. Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for Arboviruses with clinical and immunological insights.
Le Hir A; Durand GA; Boucraut J; Garnier A; Mura M; Diamantis S; Carles M; Durand C; Schweitzer C; Audouard C; Decroix V; Boyez R; Van Dendriessche A; Leclancher A; Kaphan E; Barbat du Closel L; Verdon R; du Cheyron D; Vabret A; Vergnon D; Grard G; Charrel R; de Lamballerie X; Eldin C
J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38123499
[TBL] [Abstract][Full Text] [Related]
14. MEK/ERK activation plays a decisive role in yellow fever virus replication: implication as an antiviral therapeutic target.
Albarnaz JD; De Oliveira LC; Torres AA; Palhares RM; Casteluber MC; Rodrigues CM; Cardozo PL; De Souza AM; Pacca CC; Ferreira PC; Kroon EG; Nogueira ML; Bonjardim CA
Antiviral Res; 2014 Nov; 111():82-92. PubMed ID: 25241249
[TBL] [Abstract][Full Text] [Related]
15. Limited evolution of the yellow fever virus 17d in a mouse infection model.
Kum DB; Mishra N; Vrancken B; Thibaut HJ; Wilder-Smith A; Lemey P; Neyts J; Dallmeier K
Emerg Microbes Infect; 2019; 8(1):1734-1746. PubMed ID: 31797751
[TBL] [Abstract][Full Text] [Related]
16. Establishment of Vero cell lines persistently harboring a yellow fever virus 17D subgenomic replicon.
Saito K; Shimasaki K; Fukasawa M; Suzuki R; Okemoto-Nakamura Y; Katoh K; Takasaki T; Hanada K
Virus Res; 2022 Dec; 322():198935. PubMed ID: 36152929
[TBL] [Abstract][Full Text] [Related]
17. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
[TBL] [Abstract][Full Text] [Related]
18. Generation of a reporter yellow fever virus for high throughput antiviral assays.
Sanchez-Velazquez R; de Lorenzo G; Tandavanitj R; Setthapramote C; Bredenbeek PJ; Bozzacco L; MacDonald MR; Clark JJ; Rice CM; Patel AH; Kohl A; Varjak M
Antiviral Res; 2020 Nov; 183():104939. PubMed ID: 32980446
[TBL] [Abstract][Full Text] [Related]
19. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.
Mudd PA; Piaskowski SM; Neves PC; Rudersdorf R; Kolar HL; Eernisse CM; Weisgrau KL; de Santana MG; Wilson NA; Bonaldo MC; Galler R; Rakasz EG; Watkins DI
Immunogenetics; 2010 Sep; 62(9):593-600. PubMed ID: 20607226
[TBL] [Abstract][Full Text] [Related]
20. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
